Advertisement
SAN DIEGO, Calif., Sept. 29, 2016 /PRNewswire/ -- GenomeDx Biosciences today announced that it has launched an expanded version of its Decipher GRIDŽ Tumor RNA Expression Profile, a report generated for prostate tumors profiled with a Decipher Prostate Cancer Classifier test. The report features new markers and genomic signatures characterizing specific genomic attributes of the patients' prostate cancer. The GRID Tumor RNA Expression Profile analyzes a multitude of molecular pathways and genomic signatures to enable physicians to better understand the unique attributes of the tumor.
The GRID Tumor RNA Expression Profile provides information to physicians, for Research Use Only, for every tumor profiled with a Decipher Prostate Cancer Classifier, a CLIA-validated genomic prognostic test for predicting tumor aggressiveness. GenomeDx hopes that the GRID Tumor RNA Expression Profile can ultimately enable physicians to personalize the care of their prostate cancer patients. Genomic signatures and expression levels can further characterize the tumor's biology in a way not available through traditional clinical measures alone, revealing molecular subtypes, proliferation and additional predictors of tumor grade, stage and metastasis risk. In addition, the findings may better predict a patient's response to radiation therapy, androgen deprivation therapy, or specific oncologic drugs, such as those targeting key immuno-oncology markers PD-1, PD-L1 and CTLA-4.
"The expanded GRID Tumor RNA Expression Profile showcases the power of GRID and the potential of collaborative genomics to drive new diagnostic and treatment options for cancer patients," said Jill Collins, Ph.D., Vice President of Strategic Development at GenomeDx. "Physicians who utilize GRID are able to assess the biological behavior of a patient's tumor based on analytically validated genomic signatures, providing enhanced genomic understanding of a patient's tumor which can enable a more personalized treatment pathway. We are currently working with our research collaborators to clinically validate these new signatures to move them into full clinical practice."
"The ability of genomics to transform the management of cancer care is a powerful tool," said Neal Shore, M.D., F.A.C.S., medical director of the Carolina Urologic Research Center. "The expanded GRID Tumor RNA Expression Profile is expected to provide enhanced understanding of different tumor subtypes, and why a particular treatment may or may not work. Once the new signatures are clinically validated and moved into practice, the valuable information they provide might better direct clinicians and patients toward more efficient therapeutic selections and optimized outcomes."
Decipher GRID is a cloud-based genomic data sharing and collaborative research platform that provides a foundation for discovery and innovation in urologic cancer. The GRID database contains over 27,000 tumor profiles and is growing rapidly. The information contained within the GRID Tumor RNA Expression Profile is for Research Use Only purposes, and many of the newly added genomic signatures are being tested in clinical trials. If successfully validated, these signatures will be made available for all Decipher users for routine clinical use. Additional details about accessing these tumor profiles or joining the GRID research program are available at www.DecipherGRID.com.
About DecipherŽ Prostate Cancer Classifier TestsOur Decipher Prostate Cancer Classifier tests currently include Decipher Biopsy and Decipher Post-Op. These commercially available genomic tests provide an assessment of tumor aggressiveness based on the patient's unique genomic profile. Decipher Biopsy is indicated for men with localized prostate cancer after biopsy diagnosis and Decipher Post-Op is indicated for men after prostate removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups to better determine which patients will likely benefit from additional treatment and which will not, thereby enabling improved decision-making and helping low-risk patients avoid unnecessary treatments that have serious adverse side effects and result in unnecessary costs to the healthcare system. Studies of thousands of patients from leading cancer centers, published in multiple peer-reviewed journals, demonstrate that the Decipher tests can more accurately predict disease aggressiveness than traditional clinical measures, such as PSA and Gleason score. Decipher Post-Op is covered by Medicare and by a number of private payors and preferred provider organizations representing, together with Medicare, about 70% of the approximately 66 million adult men in the United States age 40 or older who are at increased risk of being diagnosed with prostate cancer.
About Decipher GRIDŽOur Decipher Genomics Resource Information Database (Decipher GRID) is a genomic expression database that provides a foundation for open and interactive research collaboration and knowledge creation. Decipher GRID is a rapidly growing database that contains genomic profiles of thousands of patient tumors, and constitutes what we believe to be the world's largest shared, clinically-annotated genomic expression database in urologic cancer as well as one of the world's largest global RNA expression databases utilizing cloud-based analytics. We believe Decipher GRID gives rise to new opportunities for information technology-enabled genomic solutions and enables us to more rapidly discover, develop, commercialize and drive the adoption of our existing and new genomic tests. Through Decipher GRID, GenomeDx is building a suite of genomic tests in urologic cancer that we believe will allow us to achieve our goals of reducing costs to the healthcare system and improving patient lives, from screening through late-stage therapy.
About GenomeDx BiosciencesGenomeDx Biosciences uses the power of collaborative genomics to transform the management and treatment of cancer patients. GenomeDx has built Decipher GRID, a large genomics database in urologic cancer that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that are intended to provide more accurate and useful diagnostic information than both traditional diagnostic tools and existing genomic tests. GenomeDx's Decipher Biopsy and Decipher Post-Op are commercially available prostate cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient's unique genomic profile. GenomeDx is headquartered in Vancouver, British Columbia and has offices in San Diego, California.
Learn more at www.GenomeDx.com
Advertisement
The GRID Tumor RNA Expression Profile provides information to physicians, for Research Use Only, for every tumor profiled with a Decipher Prostate Cancer Classifier, a CLIA-validated genomic prognostic test for predicting tumor aggressiveness. GenomeDx hopes that the GRID Tumor RNA Expression Profile can ultimately enable physicians to personalize the care of their prostate cancer patients. Genomic signatures and expression levels can further characterize the tumor's biology in a way not available through traditional clinical measures alone, revealing molecular subtypes, proliferation and additional predictors of tumor grade, stage and metastasis risk. In addition, the findings may better predict a patient's response to radiation therapy, androgen deprivation therapy, or specific oncologic drugs, such as those targeting key immuno-oncology markers PD-1, PD-L1 and CTLA-4.
"The expanded GRID Tumor RNA Expression Profile showcases the power of GRID and the potential of collaborative genomics to drive new diagnostic and treatment options for cancer patients," said Jill Collins, Ph.D., Vice President of Strategic Development at GenomeDx. "Physicians who utilize GRID are able to assess the biological behavior of a patient's tumor based on analytically validated genomic signatures, providing enhanced genomic understanding of a patient's tumor which can enable a more personalized treatment pathway. We are currently working with our research collaborators to clinically validate these new signatures to move them into full clinical practice."
"The ability of genomics to transform the management of cancer care is a powerful tool," said Neal Shore, M.D., F.A.C.S., medical director of the Carolina Urologic Research Center. "The expanded GRID Tumor RNA Expression Profile is expected to provide enhanced understanding of different tumor subtypes, and why a particular treatment may or may not work. Once the new signatures are clinically validated and moved into practice, the valuable information they provide might better direct clinicians and patients toward more efficient therapeutic selections and optimized outcomes."
Decipher GRID is a cloud-based genomic data sharing and collaborative research platform that provides a foundation for discovery and innovation in urologic cancer. The GRID database contains over 27,000 tumor profiles and is growing rapidly. The information contained within the GRID Tumor RNA Expression Profile is for Research Use Only purposes, and many of the newly added genomic signatures are being tested in clinical trials. If successfully validated, these signatures will be made available for all Decipher users for routine clinical use. Additional details about accessing these tumor profiles or joining the GRID research program are available at www.DecipherGRID.com.
About DecipherŽ Prostate Cancer Classifier TestsOur Decipher Prostate Cancer Classifier tests currently include Decipher Biopsy and Decipher Post-Op. These commercially available genomic tests provide an assessment of tumor aggressiveness based on the patient's unique genomic profile. Decipher Biopsy is indicated for men with localized prostate cancer after biopsy diagnosis and Decipher Post-Op is indicated for men after prostate removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups to better determine which patients will likely benefit from additional treatment and which will not, thereby enabling improved decision-making and helping low-risk patients avoid unnecessary treatments that have serious adverse side effects and result in unnecessary costs to the healthcare system. Studies of thousands of patients from leading cancer centers, published in multiple peer-reviewed journals, demonstrate that the Decipher tests can more accurately predict disease aggressiveness than traditional clinical measures, such as PSA and Gleason score. Decipher Post-Op is covered by Medicare and by a number of private payors and preferred provider organizations representing, together with Medicare, about 70% of the approximately 66 million adult men in the United States age 40 or older who are at increased risk of being diagnosed with prostate cancer.
About Decipher GRIDŽOur Decipher Genomics Resource Information Database (Decipher GRID) is a genomic expression database that provides a foundation for open and interactive research collaboration and knowledge creation. Decipher GRID is a rapidly growing database that contains genomic profiles of thousands of patient tumors, and constitutes what we believe to be the world's largest shared, clinically-annotated genomic expression database in urologic cancer as well as one of the world's largest global RNA expression databases utilizing cloud-based analytics. We believe Decipher GRID gives rise to new opportunities for information technology-enabled genomic solutions and enables us to more rapidly discover, develop, commercialize and drive the adoption of our existing and new genomic tests. Through Decipher GRID, GenomeDx is building a suite of genomic tests in urologic cancer that we believe will allow us to achieve our goals of reducing costs to the healthcare system and improving patient lives, from screening through late-stage therapy.
About GenomeDx BiosciencesGenomeDx Biosciences uses the power of collaborative genomics to transform the management and treatment of cancer patients. GenomeDx has built Decipher GRID, a large genomics database in urologic cancer that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that are intended to provide more accurate and useful diagnostic information than both traditional diagnostic tools and existing genomic tests. GenomeDx's Decipher Biopsy and Decipher Post-Op are commercially available prostate cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient's unique genomic profile. GenomeDx is headquartered in Vancouver, British Columbia and has offices in San Diego, California.
Learn more at www.GenomeDx.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/genomedx-launches-expanded-grid-tumor-profiling-to-provide-enhanced-genomic-understanding-of-patients-prostate-cancer-300336287.html
SOURCE GenomeDx Biosciences
